BMCM
GMAB icon

Burns Matteson Capital Management’s Genmab GMAB Stock Holding History

Burns Matteson Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,322
Closed -$331K – 216
2026
Q1 		$331K Buy
12,322
+4,738
+62% +$142K 0.12% 157
2025
Q4 		$234K Buy
+7,584
New +$236K 0.08% 176

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Burns Matteson Capital Management's GMAB Position: Q2 2026 in Review

Burns Matteson Capital Management sold out of Genmab (GMAB) in Q2 2026, closing a stake of 12,322 shares — an estimated $331K sold.

Burns Matteson Capital Management first reported a position in GMAB in Q4 2025 and held it in 2 quarters. The position peaked at $331K in Q1 2026. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Burns Matteson Capital Management reported no remaining Genmab position as of Q2 2026 after selling out during the quarter.
  • Burns Matteson Capital Management sold 12,322 Genmab shares in Q2 2026, an estimated $331K.
  • Burns Matteson Capital Management first reported a position in Genmab in Q4 2025 and held it in 2 quarters.
  • Burns Matteson Capital Management's Genmab position peaked at $331K in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Burns Matteson Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.